Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai/Noile-Immune Ink Deal for PRIME CAR-T Technology to Create Solid Tumor Therapy
August 23, 2022
- Swiss Licensee ObsEva Withdraws NDA for Kissei’s Linzagolix in US
August 23, 2022
- Otsuka/Astex’s AML Medicine Accepted for Review in Europe
August 23, 2022
- Kyowa Kirin Bags European Approval for Crysvita in TIO
August 22, 2022
- Xofluza Approved in US for Children Aged 5 and Older
August 22, 2022
- Lagevrio Joins NHI Price List, Normal Distribution to Start Once Ready
August 19, 2022
- Astellas’ Hot Flash Med Accepted by FDA Review, Gets Short-Cut with Voucher Use
August 19, 2022
- Mochida to Roll Out Once-Daily Epadel on Sept. 12
August 19, 2022
- Forxiga Replaces Januvia as Japan’s No. 1 Diabetes Drug in April-June: IQVIA
August 18, 2022
- Incyte Japan Urges Reward for Innovation in Rare Diseases as Pemazyre Filed for Ultra Orphan Cancer
August 18, 2022
- Solasia, Nippon Kayaku to Launch PTCL Drug Darvias on Aug. 22
August 18, 2022
- Enhertu Smashes Primary Goal in PIII for HER2 Positive Metastatic Breast Cancer
August 18, 2022
- RaQualia Ties Up with Intracellular Antibody Upstart on Drug Discovery
August 17, 2022
- Japan’s First Long-Acting Injectable HIV Drug Holds Great Promise: ViiV Local Chief
August 17, 2022
- Edirol’s Tablet Forms Approved in Japan, Towa Responsible for Distribution
August 16, 2022
- US Arbitrator Rejects Seagen’s Claims against Daiichi Sankyo in ADC Feud
August 16, 2022
- UCB Files E Keppra for Children Aged One Month or Older
August 15, 2022
- Enhertu Gets Accelerated FDA Approval for 2nd Line NSCLC Use
August 15, 2022
- Chugai Gets Priority Review for PNH Med Crovalimab in China
August 12, 2022
- Sumitomo Pharma to Rev Up R&D for Regenerative Medicine, CNS towards Later 2030s
August 12, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…